SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Sees Significant Growth in Short Interest

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) saw a significant growth in short interest in March. As of March 31st, there was short interest totalling 13,700 shares, a growth of 585.0% from the March 15th total of 2,000 shares. Based on an average daily trading volume, of 25,700 shares, the short-interest ratio is presently 0.5 days.

SAB Biotherapeutics Stock Down 16.5 %

Shares of SABSW traded down $0.00 during trading hours on Wednesday, reaching $0.02. The stock had a trading volume of 1,200 shares, compared to its average volume of 22,716. The company’s 50-day moving average is $0.03 and its two-hundred day moving average is $0.05. SAB Biotherapeutics has a 12 month low of $0.01 and a 12 month high of $0.18.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.